Granocyte® (lenograstim): Risk of capillary leak syndrome
2014.03.20
Active substance: lenograstim
The company Chugai Pharma Marketing is circulating information on the occurrence of capillary leak syndrome (CLS) following administration of lenogastrim (as also in the case of other G-CSF products) in patients undergoing chemotherapy, as well as in a healthy donor during mobilisation of peripheral blood stem cells.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN